

# CITATION REPORT

List of articles citing

## Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?

DOI: 10.1016/j.eursup.2005.04.004

European Urology Supplements, 2005, 4, 14-19.

**Source:** <https://exaly.com/paper-pdf/39131008/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
34	Eligard® : Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability. <i>European Urology Supplements</i> , <b>2005</b> , 4, 20-25	0.9	22
33	Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer. <i>European Urology Supplements</i> , <b>2005</b> , 4, 4-13	0.9	9
32	Expert Opinion on Optimal Testosterone Control in Prostate Cancer. <i>European Urology Supplements</i> , <b>2005</b> , 4, 37-41	0.9	30
31	Introduction and Conclusions. <i>European Urology Supplements</i> , <b>2006</b> , 5, 887-889	0.9	
30	Eligard® : Advantages for Optimal Testosterone Control. <i>European Urology Supplements</i> , <b>2006</b> , 5, 900-904	0.9	6
29	Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 1685-99	4	4
28	Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 649-55	2.5	30
27	Optimal Testosterone Control and Eligard® . <i>European Urology Supplements</i> , <b>2007</b> , 6, 754-760	0.9	7
26	Eligard® 6: Achieving Optimal Testosterone Control with the Convenience of a Twice-a-Year Formulation. <i>European Urology Supplements</i> , <b>2007</b> , 6, 840-845	0.9	4
25	Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. <i>Journal of Urology</i> , <b>2007</b> , 178, 1290-5	2.5	199
24	Interview with Professor Ulf Tunn: LHRHa: What's new? Interview by Christine McKillop. <i>European Urology</i> , <b>2007</b> , 51, 275-7	10.2	2
23	Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. <i>BJU International</i> , <b>2008</b> , 101, 1096-100	5.6	16
22	Editorial comment on: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. <i>European Urology</i> , <b>2008</b> , 54, 814	10.2	
21	[Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy]. <i>Progres En Urologie</i> , <b>2008</b> , 18, 2-8	0.9	2
20	Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. <i>BJU International</i> , <b>2009</b> , 103, 332-5; discussion 335	5.6	43
19	GnRH blockers: a changing paradigm in the management of prostate cancer. <i>International Journal of Urological Nursing</i> , <b>2009</b> , 3, 85-92	0.8	5
18	Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?. <i>BJU International</i> , <b>2010</b> , 105, 648-51	5.6	110

17	Should we follow-up serum testosterone in patients with advanced prostate cancer?. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1031-5	3.5	0
16	[New perspectives in prostate cancer management]. <i>Progres En Urologie</i> , <b>2010</b> , 20, 491-7	0.9	0
15	Thymic involution: where endocrinology meets immunology. <i>NeuroImmunoModulation</i> , <b>2011</b> , 18, 281-9	2.5	38
14	A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. <i>Journal of Urology</i> , <b>2011</b> , 186, 889-97	2.5	105
13	Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. <i>International Urology and Nephrology</i> , <b>2012</b> , 44, 1039-44	2.3	18
12	The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. <i>Urology</i> , <b>2012</b> , 80, 174-80	1.6	23
11	Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2012</b> , 129, 179-90	5.1	8
10	New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2013</b> , 16, 7-15	6.2	46
9	Experience with degarelix in the treatment of prostate cancer. <i>Therapeutic Advances in Urology</i> , <b>2013</b> , 5, 11-24	3.2	32
8	Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. <i>European Urology</i> , <b>2014</b> , 66, 1101-8	10.2	71
7	Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. <i>Urology</i> , <b>2014</b> , 83, 1122-8	1.6	41
6	Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations. <i>American Journal of Mens Health</i> , <b>2015</b> , 9, 430-4	2.2	4
5	The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. <i>World Journal of Urology</i> , <b>2016</b> , 34, 1601-1609 <sup>4</sup>		31
4	Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. <i>Actas Urológicas Españolas (English Edition)</i> , <b>2016</b> , 40, 477-484	0.1	2
3	Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. <i>Actas Urológicas Españolas</i> , <b>2016</b> , 40, 477-84	0.7	9
2	Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. <i>Drugs</i> , <b>2017</b> , 77, 951-965	12.1	12
1	Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone. <i>Prostate</i> , <b>2017</b> , 77, 114-120	4.2	8